Some desperation elsewhere in basherville. Some pe
Post# of 72447
(Total Views: 181)
Posted On: 09/25/2017 10:21:59 PM
Some desperation elsewhere in basherville. Some people who post in both places have done well answering the 3 names who were on the bashing shift today.
The line of attack now seems to be complaints about Leo not having gambled the company's entire future on one drug trial -- by spending 30 million on a clinical trial for Brilacidin-ABSSSI, instead of spending much less to do the Bril-OM, Bril-UP, Prurisol, and 2nd Kevetrin trial -- all of which will finish much sooner than the ABSSSI trial would have --
my opinion is that if Leo had gambled the company on one clinical trial that was going to take 2 years and have to enroll thousands of patients, an awful lot of people would have sold their stock and moved on. That's probably why the bashers are so mad that he didn't do it.
And I find it very amusing now that the very people who were screaming about how there would have to be lots of dilution of stock and how bad that would be, are now the ones who say he should have raised the 30 million by diluting stock, and the fact that he didn't makes him a "liar."
Well, you see, the thing is, the current new shelf registration hasn't diluted the stock by a single share, because no shares have been issued yet. And, indeed the fact that we now have this new potential source of funding means that the company is in a MUCH stronger bargaining position with potential partners. We don't have to have one to survive.
Sorry (not sorry) to disappoint the bashers, but Leo made all the right decisions about which clinical trials to pursue. Much as I'd like to see a trial roaring along for Bril-ABSSSI, not if it would have put the company in danger. And it would have.
The line of attack now seems to be complaints about Leo not having gambled the company's entire future on one drug trial -- by spending 30 million on a clinical trial for Brilacidin-ABSSSI, instead of spending much less to do the Bril-OM, Bril-UP, Prurisol, and 2nd Kevetrin trial -- all of which will finish much sooner than the ABSSSI trial would have --
my opinion is that if Leo had gambled the company on one clinical trial that was going to take 2 years and have to enroll thousands of patients, an awful lot of people would have sold their stock and moved on. That's probably why the bashers are so mad that he didn't do it.
And I find it very amusing now that the very people who were screaming about how there would have to be lots of dilution of stock and how bad that would be, are now the ones who say he should have raised the 30 million by diluting stock, and the fact that he didn't makes him a "liar."
Well, you see, the thing is, the current new shelf registration hasn't diluted the stock by a single share, because no shares have been issued yet. And, indeed the fact that we now have this new potential source of funding means that the company is in a MUCH stronger bargaining position with potential partners. We don't have to have one to survive.
Sorry (not sorry) to disappoint the bashers, but Leo made all the right decisions about which clinical trials to pursue. Much as I'd like to see a trial roaring along for Bril-ABSSSI, not if it would have put the company in danger. And it would have.
(3)
(0)